This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Pathology & Laboratory Medicine  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Confusion and Clarity

Roger J. Pomerantz, MD

JAMA. 2001;286:2597-2599.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Highly active antiretroviral therapy (HAART) has changed the landscape of human immunodeficiency virus (HIV) care in the developed world. Many patients with access to antiretroviral therapy (ART) have benefited from the dramatic reductions in mortality and morbidity, and HIV disease has become one of relative chronicity for most but not all infected patients.^1-3

The success of HAART has now led to research into approaches to rid virally suppressed patients of residual HIV reservoirs.⁴ Nonetheless, as with several chronic diseases, the treatment often has significant adverse effects.⁵ This is the case with virtually all drugs in the various classes of antiretroviral compounds approved by the Food and Drug Administration.⁵ As such, physicians have dealt with a pendulum effect in decisions regarding when to initiate therapy during HIV infection.^5-7

Following the development of HAART, many physicians were quite aggressive in treating patients at virtually any stage of this . . . [Full Text of this Article]

Author Affiliation: Center for Human Virology, Dorrance H. Hamilton Laboratories, Departments of Medicine, Biochemistry, and Molecular Pharmacology, Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, Pa.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load
Andrew N. Phillips, Schlomo Staszewski, Rainer Weber, Ole Kirk, Patrick Francioli, Veronica Miller, Pietro Vernazza, Jens D. Lundgren, Bruno Ledergerber, and for the Swiss HIV Cohort Study, the Frankfurt HIV Clinic Cohort, and the EuroSIDA Study Group
JAMA. 2001;286(20):2560-2567.
ABSTRACT | FULL TEXT  

Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug Therapy
Robert S. Hogg, Benita Yip, Keith J. Chan, Evan Wood, Kevin J. P. Craib, Michael V. O'Shaughnessy, and Julio S. G. Montaner
JAMA. 2001;286(20):2568-2577.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine
Lampinen et al.
CMAJ 2005;172:479-483.
ABSTRACT | FULL TEXT  

Population-Based Hematologic and Immunologic Reference Values for a Healthy Ugandan Population
Lugada et al.
CVI 2004;11:29-34.
ABSTRACT | FULL TEXT  

When to Start HIV Treatment: A Work in Progress
JWatch Gastroenterology 2002;2002:12-12.
FULL TEXT  

When to Start Antiretrovirals: Later May Be Fine
AIDS Clin Care 2002;2002:1-1.
FULL TEXT  

When to Start HIV Treatment: A Work in Progress
JWatch General 2001;2001:1-1.
FULL TEXT  

Inhalational Anthrax after Bioterrorism Exposure: Spectrum of Imaging Findings in Two Surviving Patients
Earls et al.
Radiology 2002;222:305-312.
ABSTRACT | FULL TEXT